Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento’s Portfolio of COVID-19 Products in Mexico and Parts of Latin America

NEXT STORY
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
PREV STORY
TRIOSE Named a Top Fundraiser by Alex’s Lemonade Stand Foundation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of ...

author_avatar
NASDAQ Market News

OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2019 Third Quarter Results

author_avatar
NASDAQ Market News